Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
Key facts
- Where
- Changchun, Harbin, Jining, Lanzhou, Nanjing, Xian, Xuzhou és Zhengzhou, KínaSee the 10 sites
Where in Kína
- The First Hospital of Jilin UniversityChangchun, KínaNo longer taking part
- Harbin Second HospitalHarbin, KínaNo longer taking part
- The Fourth Affiliated Hospital of Harbin Medical UniversityHarbin, KínaNo longer taking part
- Affiliated Hospital of Jining Medical UniversityJining, KínaNo longer taking part
- Gansu Provincial People's HospitalLanzhou, KínaNo longer taking part
- Jiangsu Geriatric HospitalNanjing, KínaNo longer taking part
- Jiangsu Provincial Hospital of Traditional Chinese MedicineNanjing, KínaNo longer taking part
- Xian Changan District HospitalXian, KínaNo longer taking part
- Xuzhou Hospital of Traditional Chinese MedicineXuzhou, KínaNo longer taking part
- Henan Provincial People's HospitalZhengzhou, KínaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ying Gao
- Trial code
- NCT06861426
- Record updated
- 2025. március 6.
- Original description
The primary purpose of this study is to investigate the effectiveness of Ginkgo Diterpene Lactone Meglumine (GDLM) for patients with acute ischemic stroke (AIS) in real-world settings.Read full original descriptionShow less
Patients with Acute Ischemic Stroke Receiving Ginkgo Diterpene Lactone Meglumine: a Patient Registry
The primary purpose of this study is to investigate the effectiveness of Ginkgo Diterpene Lactone Meglumine (GDLM) for patients with acute ischemic stroke (AIS) in real-world settings.
Inclusion: aged ≥18 years, regardless of gender; within 48 hours of stroke onset of ischemic stroke; patient or their legally authorized representative (LAR) has signed informed consent or legally authorized oral consent with documentation.
Exclusion: mRS score of 2 or more prior to onset; inability to comply with study procedures due to documented psychiatric disorders or severe cognitive impairment; total hospital stay less than 7 days; use of other ginkgo-derived preparations except GDLM; current or planned participation in any other interventional clinical trials.